U.S. Court Backs U.S. FDA Over Wyeth's Plea To Protect Zosyn From Orchid's Generic Copies
MUMBAI - In a blow to Wyeth in its attempts to protect anti-bacterial combination injection Zosyn (piperacillin/tazobactum), the U.S. District Court of Columbia dismised a plea for a temporary restraining order against the U.S. FDA's decision to approve generic copies of the drug from India's Orchid Chemicals
More from Archive
More from Scrip
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?